Vestal Point Capital, LP Increases Stake in Alto Neuroscience, Inc. to 6.5%

On May 15, 2026, Vestal Point Capital, LP filed a Schedule 13G/A with the SEC, reporting a 6.5% ownership stake in Alto Neuroscience, Inc. (ANRO). The filing indicates that the reporting persons, which include Vestal Point Capital, LP and its Managing Partner, Ryan Wilder, beneficially own 2,064,075 shares of Common Stock. This represents an increase from a previously reported 0.0% position, as noted in the supplemental data. The shares are held directly by a specific fund and a managed account for which Vestal Point Capital, LP serves as the investment adviser. The reporting persons share voting and dispositive power over the reported shares. The filing was made pursuant to Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The calculation of the ownership percentage is based on 31,945,516 shares of Common Stock outstanding as of March 9, 2026.